title: One-step nucleic acid amplification (OSNA) for the detection of sentinel lymph node metastasis in endometrial cancer.
abstract: To evaluate the efficacy of one-step nucleic acid amplification (OSNA) for the diagnosis of sentinel lymph node (SLN) metastasis compared with histopathological examination in patients with endometrial carcinoma.
  
  
  
  A total of 94 SLNs from 34 patients with endometrial carcinoma were enrolled. The central 1-mm portion of each node was subjected to semi-serial sectioning, sliced at 200-μm intervals and examined by hematoxylin and eosin and cytokeratin 19 (CK19) immunohistochemical staining, and the remaining tissue was analysed by OSNA using CK19 mRNA. The accuracy of the OSNA assay was evaluated based on histopathological diagnosis.
  
  
  
  Histologically, 89 SLNs were determined to be metastasis negative, and the remaining five SLNs were metastasis positive. Using the breast cancer cutoff value for detecting lymph node metastasis (OSNA criteria for breast cancer, >250copies/μl) the sensitivity of the OSNA assay was 100%; specificity was 87.6%; diagnostic accuracy was 88.3%. Discordant results were recorded for 11 of 94 SLNs. In all 11 cases, a positive result was given by the OSNA assay but not by histopathological examination. In two SLNs from the same patient, histopathological examination revealed the presence of benign epithelial inclusions that were CK19 positive; both SLNs yielded a positive result in the OSNA assay (true-false positive). All remaining nine histologically-negative/OSNA-positive SLNs were classified as micrometastasis (+) by the OSNA assay.
  
  
  
  The OSNA assay shows high sensitivity and specificity, which suggests its utility as a novel tool for the molecular detection of SLN metastasis in patients with endometrial carcinoma.
authors: Department of Pathology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. Electronic address: elelenaz@hotmail.com.
authors: María E
authors: ME
authors: López-Ruiz
authors: Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; Gynecologic Oncology Group, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. Electronic address: mdtejeda@gmail.com.
authors: María D
authors: MD
authors: Diestro
authors: Department of Pathology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. Electronic address: laurayeb@yahoo.es.
authors: Laura
authors: L
authors: Yébenes
authors: Department of Pathology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. Electronic address: alberto.berjon@gmail.com.
authors: Alberto
authors: A
authors: Berjón
authors: Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. Electronic address: begodelanoval@gmail.com.
authors: Begoña
authors: B
authors: Díaz de la Noval
authors: Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. Electronic address: marta.mendiola@gmail.com.
authors: Marta
authors: M
authors: Mendiola
authors: Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. Electronic address: jsantiagog@hotmail.es.
authors: Javier
authors: J
authors: De Santiago
authors: Department of Pathology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. Electronic address: david.hardisson@salud.madrid.org.
authors: David
authors: D
authors: Hardisson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016889:Endometrial Neoplasms / Q000473:pathology*; D005260:Female; D018628:Gene Dosage; D006801:Humans; D053539:Keratin-19 / Q000235:genetics*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D021141:Nucleic Acid Amplification Techniques; D000071036:Sentinel Lymph Node / Q000473:pathology*
chemical_list: D053539:Keratin-19
keywords: Cytokeratin 19; Endometrial cancer; Lymph node metastasis; OSNA; One-step nucleic acid amplification; Sentinel lymph node biopsy; Ultrastaging